Here’s What Analysts Think About Pfizer Inc. (PFE)

Group 1 - Pfizer Inc. is considered one of the best affordable healthcare stocks to buy, with a Buy rating from Scotiabank analyst Louise Chen and a price target of $30.00 [1] - Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer with the same price target of $30.00 [1] - BofA analyst Jason Gerberry reduced the price target for Pfizer from $28 to $27 while keeping a Neutral rating, citing faster erosion of COVID-19 product sales as a reason [2] Group 2 - Pfizer announced positive topline results from the Phase 3 EV-304 clinical trial for PADCEV™, showing significant improvements in survival for patients with muscle-invasive bladder cancer [3] - The combination of PADCEV and Keytruda is the first regimen without platinum-based chemotherapy to improve event-free and overall survival in cisplatin-eligible patients [4] - Pfizer is a global biopharmaceutical company focused on wellness, prevention, treatment, and cures in various markets [4]